Decitabine combined with reduced-intensity conditioning for older patients with acute myeloid leukemia in composite complete remission undergoing allogeneic hematopoietic stem cell transplantation: a multicenter, single-arm, phase 2 trial.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 40831735.
- Also identified by DOI 10.1016/j.lanwpc.2025.101664 and PMC identifier 12359252.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Outcomes of older patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem-cell transplantation (allo-HSCT) remain unsatisfactory. The primary objective of this trial was to establish whether decitabine combined with reduced-intensity conditioning (RIC) regimen could improve overall survival (OS) for this population in composite complete remission (CRc). We conducted a single-arm, phase 2 trial at six hospitals in China. Eligible patients were aged 60-80 years, had a diagnosis of AML, achieved CRc at transplantation, were willing to undergo the first allo-HSCT, and had an Eastern Cooperative Oncology Group performance status of 0-2. Patients received decitabine combined with RIC regimen, comprising decitabine 20 mg/m<sup>2</sup> daily intravenously (days -9 to -7), busulfan 3.2 mg/kg daily intravenously (days -5 to -4), and fludarabine 30 mg/m<sup>2</sup> daily intravenously (days -6 to -3). The primary endpoint was 2-year OS rate. All efficacy and safety endpoints were assessed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov (NCT03530085) and is complete. Between Jan 1, 2021 and Nov 30, 2022, 60 patients were enrolled. With a median follow-up of 35.5 months (IQR 32.5-39.2), 39 patients survived and 21 died. The 2-year OS rate was 67% (95% CI 56-80), which met the primary objective. Within 100 days post-transplantation, the most common grade 3-4 non-hematological treatment-emergent adverse events (TEAEs) were infections (22 [37%]), acute graft-versus-host disease (21 [35%]), and gastrointestinal disorders (16 [27%]). Five (8%) patients died of TEAEs, with one death treatment-related. Decitabine combined with RIC regimen exhibits encouraging OS and acceptable toxicity profile, which might be a suitable therapeutic option for older patients with AML. National Natural Science Foundation of China; Science and Technology Program of Guangdong Province; National Key Research and Development Program of China.